Antineoplastic cell and gene therapy
- Name
- Antineoplastic cell and gene therapy
- Accession Number
- DBCAT005827
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Sitimagene ceradenovec Intended for the treatment of brain cancer. Tisagenlecleucel A CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma. Talimogene laherparepvec A genetically modified virus used to treat recurrent melanoma, or metastatic melanoma. Axicabtagene ciloleucel A CAR T-cell therapy used to treat adults with large B-cell lymphomas and follicular lymphoma. Brexucabtagene autoleucel A modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ΞΆ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma. Idecabtagene vicleucel An autologous T-cell therapy indicated to treat relapsed or refractory multiple myeloma. Ciltacabtagene autoleucel A BCMA-directed CAR T-cell therapy used in the treatment of relapsed or refractory multiple myeloma in previously treated patients. - Drugs & Drug Targets